In this study we want to find out more about how to best adjust the chemotherapy which is given before surgery (neoadjuvant chemotherapy) to maximize the effectiveness. Currently, neoadjuvant chemotherapy is given until there is a change on the radiographic images (CT scan) to suggest that the chemotherapy is not working. However, pancreatic cancers often do not demonstrate changes with imaging and therefore it is difficult to determine whether the chemotherapy is working or not. We want to find out if adding monitoring of a tumor marker (CA19-9) in your blood and assessments of your overall well-being (performance status) in addition to radiographic imaging, will help us to recognize and change chemotherapy (adaptive modification) so that we can improve the number of patients who are able to complete all neoadjuvant therapy and surgery. We don't know if this study will help you. Your condition may get better but it could stay the same or even get worse. We hope the information from this study will help us develop a better treatment for pancreatic cancer in the future.
Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic Cancer
OPEN TO ACCRUAL